Skip to Content

Clinical Trials

Last Updated: 6/19/2014

Lymphoma

Marginal Zone Lymphoma

Previously Treated

2010-0197 (Bendamustine, GA-101/Obinutuzumab): An Open-Label, Multicenter, Randomized, Phase III Study to Investigate The Efficacy and Safety Of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma.

2010-0811 (Bendamustine HCl; CAL-101; Ofatumumab; Rituximab) A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination with Chemotherapeutic Agents, Immunomodulatory Agents, and Anti-CD20 mAb in Subjects with Relapsed or Refractory Indolent B-cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.

2012-0740 (hLL1-DOXA): Phase I/II Study of Immunotherapy with hLL1-DOX in Patients
with Non-Hodgkin’s Lymphoma (NHL) and Chronic LymphocyticLeukemia (CLL)

Follicular Lymphoma

Newly Diagnosed

2011-0805 (Rituximab + Lenalidomide vs. Rituximab + Chemotherapy): A Phase 3 Open-Label Randomized Study to Compare The Efficacy and Safety of Rituximab Plus Lenalidomide Versus Rituximab Plus Chemotherapy Followed by Rituximab In Subjects with Previously Untreated Follicular Lymphoma.

2013-0897 (Ibrutinib; Rituximab): A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab in Previously Untreated Subjects with Follicular Lymphoma.

Previously Treated

2010-0197 (Bendamustine, GA-101/Obinutuzumab): An Open-Label, Multicenter, Randomized, Phase III Study to Investigate The Efficacy and Safety Of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma.

2012-0696 (BKM120): An Open-Label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma.

2012-0750 (SGN-CD19A): Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate The Safety and Tolerability Of SGN-CD19A in Patients with Relapsed Or Refractory B-Lineage Non-Hodgkin Lymphoma (Grade 3 Follicular Lymphoma).

2013-0173 (Ibrutinib): An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma

2010-0811 (Bendamustine HCl; CAL-101; Ofatumumab; Rituximab) A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination with Chemotherapeutic Agents, Immunomodulatory Agents, and Anti-CD20 mAb in Subjects with Relapsed or Refractory Indolent B-cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.

2012-0740 (hLL1-DOXA): Phase I/II Study of Immunotherapy with hLL1-DOX in Patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). 

Small Lymphocytic Leukemia 

Previously Treated

2010-0197 (Bendamustine, GA-101/Obinutuzumab): An Open-Label, Multicenter, Randomized, Phase III Study to Investigate The Efficacy and Safety Of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients With  Rituximab-  Refractory, Indolent, Non-Hodgkin's Lymphoma.

2010-0811 (Bendamustine HCl; CAL-101; Ofatumumab; Rituximab) A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination with Chemotherapeutic Agents, Immunomodulatory Agents, and Anti-CD20 mAb in Subjects with Relapsed or Refractory Indolent B-cell Non- Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.

Diffuse Large B-Cell Lymphoma

Newly Diagnosed 

2009-0793 (Everolimus/RAD001): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo after Patients have Achieved Complete Response With First-Line Rituximab Chemotherapy.

2009-0833 (Rituximab, Dose Adjusted EPOCH): Phase II Study of Dose-Adjusted Epoch+/- Rituximab In Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.

2010-0822 (Imaging): FLT-PET/CT vs. FDG-PET/CT for Therapy Monitoring of Diffuse Large B-Cell Lymphoma.

2012-0504 (Zevalin): A Phase 3, Open-Label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) vs. Observation in Patients at Least 60 Years of Age with Remission after RCHOP or RCHOP-Like Therapy.

2012-1155 (RO5072759): A Phase 3, Multicenter, Open-Label, Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination with CHOP (G-CHOP) Versus R-CHOP in Previously Untreated Patients with CD20+ DLBCL.

2013-0564 (Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine): A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) as front-line therapy in patients with diffuse large B-cell lymphoma (DLBCL).

2013-0425 (Cyclophosphamide; Doxorubicin; Ibrutinib; Prednisone; Rituximab; Vincristine) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma.

Previously Treated 

2011-0442 (Brentuximab Vedotin): A Phase 2 Study Of Brentuximab Vedotin (SGN-35) In Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphoma.

2011-0467 (AUY922): A Phase II Study of the HSP90 Inhibitor AUY922 In Patients with Relapsed and Refractory Lymphoma.

2011-0856 (Ruxolitinib): A Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma.

2012-0696 (BKM120): An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma.

2012-0750 (SGN-CD19A): Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate The Safety and Tolerability Of SGN-CD19A in Patients with Relapsed Or Refractory B-Lineage Non-Hodgkin Lymphoma. (B-NHL).

2012-0602 (MLN8237; Romidepsin) A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas.

2012-0740 (hLL1-DOXA): Phase I/II Study of Immunotherapy with hLL1-DOX in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Hodgkin's Lymphoma

Newly Diagnosed

2009-0292 (Rituximab, ABVD): Phase III Study Comparing Rituximab-Supplemented ABVD (R-ABVD) With ABVD Followed by Involved-Field Radiotherapy (ABVD-RT) In LIMITED-Stage ( I-IIA With No Areas of Bulk) Hodgkin's Lymphoma.

2012-0661 (A+AVD Versus ABVD): A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma.

2011-0104 (Adriamycin; Dacarbazine; Doxorubicin; SGN-35) A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma.

Previously Treated 

2010-0065 (Panobinostat, ICE): Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study Of ICE Compared with Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma.

Mantle Cell Lymphoma 

Newly Diagnosed

2013-0056 (Bendamustine, Rituximab, Ibrutinib): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma.

Previously Treated

2012-0188 (Carfilzomib; Lenalidomide; Rituximab) A Phase I/II Study of Carfilzomib plus Lenalidomide and Rituximab in the Treatment of relapsed/refractory Mantle Cell Lymphoma.

2012-0696 (BKM120): An Open-Label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma.

2012-0750 (SGN-CD19A): Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate The Safety and Tolerability Of SGN-CD19A in Patients with Relapsed Or Refractory B-Lineage Non-Hodgkin Lymphoma (B-NHL). 

2013-0090 (Ibrutinib + Rituximab): A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

2012-0740 (hLL1-DOXA): Phase I/II Study of Immunotherapy with hLL1-DOX in Patientsnwith Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Burkitt's Lymphoma

Newly Diagnosed

2009-0833 (Rituximab, Dose Adjusted EPOCH): Phase II Study of Dose-Adjusted Epoch+/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.

Previously Treated 

2012-0602 (MLN8237, Romidepsin):  Phase I Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Burkitt's Lymphoma (BL), Double-Hit Lymphomas (DHL), and Other C-Myc Positive B-Cell Lymphomas.

2012-0750 (SGN-CD19A): A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma.

2012-0740 (hLL1-DOXA): Phase I/II Study of Immunotherapy with hLL1-DOX in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

T-Cell Lymphoma 

Newly Diagnosed

2012-0630 (Brentuximab, CHP): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-Cell lymphomas.  

Previously Treated

2011-0183 (Carfilzomib): Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma.

2011-0467 (AUY922): A Phase II Study of the HSP90 Inhibitor AUY922 In Patients with Relapsed and Refractory Lymphoma.

2011-0856 (Ruxolitinib): A Phase 2 Multicenter, investigator initiated study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma. 

2012-0183 (Romidepsin, ICE): Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

2012-0602 (MLN8237, Romidepsin):  Phase I Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Burkitt's Lymphoma (BL), Double-Hit Lymphomas (DHL), and Other C-Myc Positive B-Cell Lymphomas.

2012-0740 (hLL1-DOXA): Phase I/II Study of Immunotherapy with hLL1-DOX in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Castleman's Disease

2010-0907 (Siltuximab): An Open-Label, Multicenter Study to Evaluate the Safety of Long-Term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease.

Myeloma

Smoldering Asymptomatic Myeloma

2012-0089 (PVX-410): A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients with Smoldering Multiple Myeloma.

Newly Diagnosed

2010-0815 (Lenalidomide, Bortezomib, Dexamethasone): A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.

2011-0192 (Lenalidomide, Bortezomib, Dexamethasone, Panobinostat): Phase I/Ib Trial of Efficacy and Safety of the Combination Therapy of Lenalidomide, Bortezomib, Dexamethasone and Panobinostat in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma.

2013-0569 (Cyclophosphamide; Dexamethasone; Lenalidomide; oprozomib): Phase Ib/2, Multicenter, Open-Label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma.

Previously Treated

2011-0144 (ARRY-520): A Phase I Study of ARRY-520 (Kinesin Inhibitor) and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.

2011-0167 (ACY-1215): A Phase I/II, Open-label, Multicenter Study of ACY-1215 (Hystone Deactylase or HDAC Inhibitor) Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed-Refractory Multiple Myeloma.

2011-0336 (Carfilzomib, Dexamethasone, Pomalidomide): A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

2012-0107 (Oral LGH447): A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma.

2012-0573 (Carfilzomib + Dexamethasone vs. Bortezomib + Dexamethasone): A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma.

2012-1159 (SCH 727965, Bortezomib, Dexamethasone): Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination with Bortezomib and Dexamethasone in Relapsed Multiple Myeloma.

2013-0624 (ATRA; Dexamethasone; Revlimid): Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.

Myeloma Patients With Renal Impairments

2012-0205 (Pomalidomide + Dexamethasone): A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety 0f Pomalidomide When Given in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma and Impaired Renal Function.

Maintenance Therapy After Stem Cell Transplant

2012-0277 (Lenalidomide, MLN 9708): Phase II Study of the Combination of MLN 9708 with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma.

2012-0413 (Minocycline): A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden during Maintenance Therapy for Multiple Myeloma.


© 2014 The University of Texas MD Anderson Cancer Center